SOMAÍ Pharmaceuticals - Dublin

Somai Pharmaceuticals LTD is an innovative European pharmaceutical and biotech company with a focus on the manufacture and distribution of GMP-certified cannabinoid-containing pharmaceuticals throughout the European Union and beyond. Leveraging strong scientific backgrounds and the competitive American market, Somai has become the largest and most advanced cannabinoid facility in Europe, producing medicines, products, and registered APIs. Somai has formed a global team of renowned scientists and KOLs from various clinical fields to guide their product development and acceptance. Education and continuous research and development are core values of the company, which has enabled them to develop treatments for the endocannabinoid system with variable dosage options for EU doctors and  

Show more

patients. With the aim of creating maximum bioavailability and healing for patients, Somai is dedicated to developing the most advanced products with the most innovative delivery methods. As a result, Somai has become one of the most renowned pharmaceutical brands in the EU, boasting a large IP vault of APIs and a pipeline of current and future products scheduled for release in late 2022. With an eye towards the future, Somai looks ahead to clinical trials for their proprietary pipeline, setting them up for success in the coming decade.